Ipsen

Ipsen Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Ipsen (IPN.PA) as of Nov 6, 2026 is 256.11 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 264.67 % — a change of -3.24% (lower).

Cash Conversion

256.11 %

YoY

-3.24%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Ipsen is 2025 256.11 % . Cash Conversion Rate (OCF/Net Income) of Ipsen was 2024 264.67 % . It decreases by -3.24% lower compared to the previous year.

The Ipsen Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
146.57 EUR
Jan 1, 2019
-1,143.35 EUR
Jan 1, 2020
140.75 EUR
Jan 1, 2021
140.61 EUR
Jan 1, 2022
149.77 EUR
Jan 1, 2023
134.37 EUR
Jan 1, 2024
264.67 EUR
Jan 1, 2025
256.11 EUR
The Ipsen Cash Conversion history
YEARCash ConversionYoY
256.11 %-3.24%
264.67 %+96.97%
134.37 %-10.28%
149.77 %+6.51%
140.61 %-0.10%
140.75 %-112.31%
-1,143.35 %-880.06%
146.57 %-5.62%
155.31 %+10.40%
140.68 %+19.48%
117.75 %-26.47%
160.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Cash Conversion Rate (OCF/Net Income) of Ipsen is 256.11 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Ipsen changed from 264.67 % to 256.11 %, representing a -3.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Ipsen since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Ipsen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ipsen

All Key Metrics — Ipsen